JD Health International, Inc. (HK:6618)
:6618
Want to see HK:6618 full AI Analyst Report?
6618 Stock Chart & Stats
HK$60.30
HK$0.45(1.61%)
At close: 4:00 PM EST
HK$60.30
HK$0.45(1.61%)
Day’s Range― - ―
52-Week RangeHK$37.20 - HK$71.70
Previous CloseN/A
Volume5.25M
Average Volume (3M)7.60M
Market Cap
HK$127.79B
Enterprise ValueHK$75.33B
Total Cash (Recent Filing)HK$47.00B
Total Debt (Recent Filing)HK$636.29M
Price to Earnings (P/E)19.5
Beta1.38
Next Earnings
Aug 13, 2026EPS Estimate
1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.68
Shares Outstanding3,210,775,100
10 Day Avg. Volume6,883,323
30 Day Avg. Volume7,596,953
Financial Highlights & Ratios
PEG Ratio1.03
Price to Book (P/B)2.65
Price to Sales (P/S)2.17
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$71.58Price Target Upside18.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)1.82
Revenue Forecast (FY)HK$86.58B
Bulls Say, Bears Say
Bulls Say
Very Low Leverage & Strong Balance SheetExceptionally low debt and rising equity give the company durable financial flexibility. This balance-sheet strength supports continued investment in supply-chain scale, self-operated pharmacies and AI initiatives, lowers refinancing risk and preserves optionality through business cycles.
Sustained Revenue Growth & ProfitabilityDouble-digit revenue growth with accelerating non-IFRS profit and margin expansion reflects scalable core e-commerce and services. Consistent top-line expansion across quarters demonstrates durable market demand, improving unit economics and the ability to fund growth without sacrificing profitability long-term.
Scale In AI, Product Launches & EcosystemLarge-scale AI engagement, rapid new-drug launches and clinical deployments build a differentiated, sticky ecosystem. These capabilities create multi-year revenue levers—improving retention, unlocking services monetization and strengthening partnerships with hospitals and device partners.
Bears Say
2025 Free Cash Flow ResetA zero free-cash-flow outcome in 2025 signals a material step-up in investment or working-capital needs that reduces near-term financial flexibility. If sustained, it may constrain organic funding for expansion or force trade-offs between growth investments and margin preservation.
Revenue Concentration In Direct SalesHigh dependence on direct-sales channels concentrates exposure to supplier terms, pricing pressure and single-category shifts. This makes revenue and margin outcomes more sensitive to competitive moves or supply disruptions versus a more diversified service mix over the medium term.
AI Monetization & Rising Operating CostsWhile AI engagement and offline experiments scale, unclear commercialization paths plus rising S&M and lower-margin offline economics can pressure returns. Sustained elevated operating spend without clear revenue conversion risks compressing long-term profitability and cash conversion.
JD Health International, Inc. News
6618 FAQ
What was JD Health International, Inc.’s price range in the past 12 months?
JD Health International, Inc. lowest stock price was HK$37.20 and its highest was HK$71.70 in the past 12 months.
What is JD Health International, Inc.’s market cap?
JD Health International, Inc.’s market cap is HK$127.79B.
When is JD Health International, Inc.’s upcoming earnings report date?
JD Health International, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 69 days.
How were JD Health International, Inc.’s earnings last quarter?
JD Health International, Inc. released its earnings results on Mar 05, 2026. The company reported HK$1.081 earnings per share for the quarter, beating the consensus estimate of HK$0.752 by HK$0.33.
Is JD Health International, Inc. overvalued?
According to Wall Street analysts JD Health International, Inc.’s price is currently Undervalued.
Does JD Health International, Inc. pay dividends?
JD Health International, Inc. does not currently pay dividends.
What is JD Health International, Inc.’s EPS estimate?
JD Health International, Inc.’s EPS estimate is 1.35.
How many shares outstanding does JD Health International, Inc. have?
JD Health International, Inc. has 3,210,775,100 shares outstanding.
What happened to JD Health International, Inc.’s price movement after its last earnings report?
JD Health International, Inc. reported an EPS of HK$1.081 in its last earnings report, beating expectations of HK$0.752. Following the earnings report the stock price went down -6.219%.
Which hedge fund is a major shareholder of JD Health International, Inc.?
Currently, no hedge funds are holding shares in HK:6618
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JD Health International, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$71.58 (18.70% Upside)
HK$71.58 (18.70% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
130.47%
12-Months-Change
Fundamentals
Return on Equity
9.11%
Trailing 12-Months
Asset Growth
19.80%
Trailing 12-Months
Company Description
JD Health International, Inc.
JD Health International Inc., an investment holding company, operates an online healthcare platform in the People's Republic of China. It offers pharmaceutical and healthcare products, including OTC drugs, prescription drugs, and medical devices and supplies, as well as health supplements and tonics through direct selling and an online retail pharmacy network. The company also provides online healthcare services, online consultation, hospital or doctor referral, health check-ups, genetic testing, and beauty care services; health management and intelligent healthcare solutions, as well as technical and advertising services. In addition, it offers access to medical checkups, medical aesthetics, vaccination appointments, dental care services, and nucleic acid testing tests. The company was incorporated in 2018 and is headquartered in Beijing, the People's Republic of China. JD Health International Inc. is a subsidiary of JD Jiankang Limited.
6618 Stock 12 Month Forecast
Average Price Target
HK$71.58
▲(18.70% Upside)
Technical Analysis
Rici Healthcare Holdings Ltd.
―
Jinxin Fertility Group Ltd.
―
Gushengtang Holdings Limited
―
Guangdong Kanghua Healthcare Co., Ltd. Class H
―
Hygeia Healthcare Holdings Co., Ltd.
―
Options Prices
Currently, No data available
---